PRPF40B

Across TCGA pan-cancer cohorts, PRPF40B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRPF40B data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher PRPF40B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRPF40B expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

KIRP, KICH, and BLCA are the cancer types where PRPF40B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.199	0.903	<.001	15	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
BLCA	DFS	Median	IV	0.114	0.484	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	1.000	0.719	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRPF40B–KIRP (OS)

Open the KIRP breakdown →